Other Specific bowel diseases
Conditions
Interventions
Intervention group: 35 extremely premature infants, weighing less than 1,500 g and up to 32 gestational weeks, admitted to the intensive care unit, the mother's own colostrum will be used and the trea
and then the same syringe containing 0.1 ml (two drops) of remaining colostrum will be administered in the left oral mucosal tissue until the twelfth. Fecal sample will be collected on the first and s
Drug
G06.373
Z29.1
H01.158.273.343.350.261
Sponsors
Jessica Santos Passos Costa
Universidade Estadual de Feira de Santana
Eligibility
Age
No minimum to 7 Days
Inclusion criteria
Inclusion criteria: The inclusion criteria for the control group (from HEC) will be: premature newborns admitted to Neonatal Units, birth weight 1,500g, 32 weeks gestational age, They must be on a zero diet orally and enteral or using total parenteral nutrition (NTP), and / or enteral administration of infant formula and clinically stable, with normal parameters. In addition, to collect the fecal sample, the newborn will be included if the first evacuation was made at the NICU. The mothers of infants, both for the group of intervention, as well as for the control group, will be selected according to the eligibility criteria of your children's entry into the study
Exclusion criteria
Exclusion criteria: Among the exclusion criteria: mother's, maternal history of substance use psychoactive drugs, drugs, alcohol, presence of psychological disorder, multiple pregnancy from triplets and children of mothers contraindicated for breastfeeding retroviruses and cytomegalovirus). RN: use of vasopressor medication bigger then 10mcg / Kg / min, requirement for immediate surgical intervention, syndromes and / or congenital malformations, neonatal morbidities such as the incidence of patent ductus arteriosus (PDA), sepsis or necrotizing enterocolitis (NEC), The newborn who eliminates meconium in the Obstetric Center (CO).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the association, through metagenomic analysis, between immunotherapy with colostrum and the intestinal microbiome colonized by bacterial species in premature newborns treated at the Unified Health System in Feira de Santana - BA | — |
Secondary
| Measure | Time frame |
|---|---|
| Describe the birth, socioeconomic and environmental variables of newborns born and their mothers, in the intervention and control group;Investigate the differences between the microbiome infection of preterm infants treated or not with colostrum;Examine the diversity of bacteria present in meconium and on the fifth day of life, through metagenomic DNA, of newborns preterm infants treated or not with colostrum;Assess the immunological profile of preterm infants treated or not with colostrum;Compare the occurrence of unfavorable outcomes (any diagnosis of health conditions of newborns) between groups | — |
Countries
Brazil
Contacts
Public ContactGraciete;Jessica Vieira;Costa
Universidade Estadual de Feira de Santana;Universidade Estadual de Feira de Santana
Outcome results
None listed